Time to Bet Big on Hims? Analysts Spotlight Explosive Growth Catalysts

Hims isn't just growing—it's rewriting the telehealth playbook. Multiple catalysts suggest this stock could be primed for a major breakout.

Market Expansion: Driving New Revenue Streams

The platform's move into additional treatment verticals creates fresh monetization opportunities without the traditional healthcare bureaucracy. Expansion into mental health and specialized treatments positions Hims to capture more wallet share.

Telehealth Adoption: Accelerating Beyond Expectations

Consumer comfort with digital health solutions continues climbing—no more waiting rooms, no pharmacy lines. Hims' model cuts out the middlemen that typically drain profitability from healthcare ventures.

Subscription Model: Recurring Revenue Engine

Monthly subscriptions create predictable cash flow—something Wall Street loves almost as much as overpriced IPOs. The model builds customer loyalty while smoothing out revenue volatility.

Brand Recognition: From Niche to Mainstream

What began as discreet men's wellness now commands broad consumer trust across demographics. That brand equity translates to lower customer acquisition costs and higher lifetime values.

Hims represents everything traditional healthcare isn't: efficient, scalable, and actually profitable. While legacy providers wrestle with paperwork, this company just keeps signing up subscribers—proving sometimes the best prescription is simply bypassing the entire broken system.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Canaccord Genuity Stays Positive

Canaccord Genuity analyst Maria Ripps kept a Buy rating and $68 price target on HIMS. The 5-star analyst said the stock’s recent weakness comes from short-term worries, rather than structural issues. Ripps explained that shifting sexual health subscribers from on-demand orders to daily plans will slow growth for a few quarters. However, this change makes the subscriber base more loyal, sets up easier comparisons in 2026, and reflects management’s ability to add and scale new treatments.

She also highlighted that recent FDA guidance, along with a court decision dismissing Eli Lilly’s (LLY) lawsuit against Willow Health for selling copycat versions of its GLP-1 drugs, adds support to Hims’ GLP-1 business. Ripps believes Hims has several ways to grow, such as new care areas, expansion overseas, and compounded GLP-1 products. These could help the company meet its 2030 targets through several potential paths.

BTIG Stays Bullish on GLP-1 Growth

Meanwhile, BTIG analyst David Larsen kept a Buy rating and set a Street-high $85 target on Hims, indicating 53% upside potential. He said the revenue slowdown in Q2 was due to the end of the bulk compounding grace period in May 2025. Still, he expects sales from 503A compounded products to rise in the second half of the year.

Larsen also thinks Hims’ forecast of about $725 million in 2025 weight-loss revenue is conservative, and believes actual sales will be much higher. He remains confident that GLP-1 growth will pick up again and sees more upside for the stock.

Is HIMS a Good Stock to Buy? 

Overall, Wall Street is sidelined on Hims & Hers Health stock, with a Hold consensus rating based on seven Holds, two Buys, and two Sell recommendations. The average HIMS stock price target of $49.00 indicates 11.71% downside potential.